RPS6KB1 and melanoma: It inhibited pAkt and pS6K levels in BrafV600E; Phd2−/− melanoma cells (Fig. 7k), and inhibited the proliferation of BrafV600E; Phd2−/− melanoma cells in a dose-dependent manner (Fig. 7l).